MGMT and melanoma: Similar to malignant gliomas, melanomas express, compared to other cancers, quite low levels of MGMT (Chen et al, 1992; Kaina et al, 2007), which might explain why melanomas respond to the methylating drugs DTIC and TMZ, but not to many other anticancer drugs.